CN101453982B - Two-piece, internal-channel osmotic delivery system flow modulator - Google Patents
Two-piece, internal-channel osmotic delivery system flow modulator Download PDFInfo
- Publication number
- CN101453982B CN101453982B CN2007800187567A CN200780018756A CN101453982B CN 101453982 B CN101453982 B CN 101453982B CN 2007800187567 A CN2007800187567 A CN 2007800187567A CN 200780018756 A CN200780018756 A CN 200780018756A CN 101453982 B CN101453982 B CN 101453982B
- Authority
- CN
- China
- Prior art keywords
- delivery system
- osmotic delivery
- container
- inner core
- shell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T137/00—Fluid handling
- Y10T137/0318—Processes
- Y10T137/0402—Cleaning, repairing, or assembling
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49229—Prime mover or fluid pump making
- Y10T29/49236—Fluid pump or compressor making
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/494—Fluidic or fluid actuated device making
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Materials For Medical Uses (AREA)
- Amplifiers (AREA)
- Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
- Prostheses (AREA)
- External Artificial Organs (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
Abstract
An osmotic delivery system flow modulator includes an outer shell constructed and arranged for positioning in an opening of a reservoir of an osmotic delivery system, an inner core inserted in the outer shell, and a fluid channel having a spiral shape defined between the outer shell and the inner core. The fluid channel is adapted for delivery of an active agent formulation from the reservoir of the osmotic delivery system.
Description
The cross reference of related application
The application requires the priority of the U.S. Provisional Application 60/809,451 on May 30th, 2006, and the content of described application is merged in this paper as a reference.
Background of invention
Relate generally to of the present invention is used for continuing at fluid environment the osmotic delivery system of active agent delivery.More specifically, the present invention relates to be used at the flow conditioner of fluid environment from the osmotic delivery system active agent delivery.
Fig. 1 has illustrated the osmotic delivery system 40 of prior art, and is described as people's such as Peterson United States Patent (USP) 6,524,305.Described delivery system 40 comprises the housing 42 that holds penetrating agent 47 and activating agent 44.Resolution element 46 forms spacer between penetrating agent 47 and activating agent 44.Semi-permeable plug 48 is inserted in first opening 45 of housing 42.Semi-permeable plug 48 optionally allows fluid to enter the inside of housing 42.Flow conditioner 20 is inserted in second opening 39 of housing 42.Flow conditioner 20 allows activating agent 44 to leave the inside of housing 42, and controls the inside of fluid back-diffusion to housing 42.When osmotic delivery system 40 is placed in the fluid environment, enter housing 42 and infiltrate penetrating agent 47 by semipermeable plug 48 from the fluid of housing 42 outsides, cause that penetrating agent 47 expands.Penetrating agent 47 moves resolution element 46 when expanding, and causes that activating agent 44 is delivered to applied environment by flow conditioner 20.
In the osmotic delivery system 40 of the prior art shown in Fig. 1, the outer surface of flow conditioner 20 comprises spiral helicine delivery path 32, activating agent 44 by described delivery path 32 from the internal circulation of housing 42 to the outside.Form the inner surface 43 of screw thread (thread) the 36 butt housings 42 of helical delivery path 32, make activating agent 44 by helical delivery path 32 time, contact the inner surface 43 of housing 42.Spacing, distance, cross-sectional area and shape to helical delivery path 32 are selected, and make that from the fluid environment to the housing back-diffusion in 42 minimizes.Filler opening 22 and steam vent 24 are provided in flow conditioner 20.When this osmotic delivery system 40 of assembling, at first flow conditioner 20 is inserted in the housing 42.By filler opening 22 activating agent 44 is expelled in the housing 42 then, and the gas in the housing 42 flows out by steam vent 24., end cap 26 be inserted in hole 22,24, make and only sending of activating agent 44 taken place by helical delivery path 32 thereafter.
From foregoing as seen, still wish the reliability and the flow adjustment ability that in osmotic delivery system, provide other.
Summary of the invention
In one aspect, the present invention relates to the osmotic delivery system flow conditioner, it comprises the shell that is configured and arranges the vessel port that is used for being positioned at osmotic delivery system, be inserted into the inner core in the shell, and the helical form flow channel that between described shell and inner core, limits, described flow channel is suitable for the container delivery of active agent formulation from osmotic delivery system.
In one aspect of the method, the present invention relates to osmotic delivery system, it comprises container; Be arranged on first end of described container, the mobile semipermeable plug that is used for optionally allowing to enter container; Be arranged on the flow conditioner of second end of described container, described flow conditioner comprises and is suitable for being delivered to internal helicoid passage in the fluid environment that described osmotic delivery system works therein with being included in active agent formulation in the container.
In a further aspect, the present invention relates to be used for the implantable delivery system of active agent formulation, it comprises the container of being made by non-permeable material, first Room that comprises the osmotic engine material in described container, second Room that comprises active agent formulation in described container, be arranged on container first terminal and the first Room adjacency semipermeable plug and be arranged on second Room of container and the aforesaid flow conditioner of the second Room adjacency.
From the following description book and the apparent other features and advantages of the present invention of claim subsequently.
Description of drawings
Description of drawings as described below typical embodiment of the present invention, and it should be thought of as and limit the scope of the invention, because the present invention can allow other same effectively embodiment.Not necessarily pro rata in the accompanying drawing, and for clarity and conciseness, some feature among the figure and some view may amplify on ratio or schematically.
Fig. 1 describes the cutaway view of prior art osmotic delivery system.
Fig. 2 A describes the phantom of flow conditioner, and described flow conditioner has inner core that is inserted in the shell and the internal helicoid flow channel that is formed in the inner core.
Fig. 2 B describes the phantom of flow conditioner, and described flow conditioner has inner core that is inserted in the shell and the internal helicoid flow channel that is formed in the shell.
Fig. 2 C describes the phantom of flow conditioner, and described flow conditioner has inner core that is inserted in the shell and the internal helicoid flow channel that is formed in inner core and the shell.
Fig. 2 D describes the phantom of flow conditioner, and described flow conditioner has inner core and the mobile insert that is inserted in the shell, and described mobile insert comprises the internal helicoid flow channel that is inserted between inner core and the shell.
Fig. 2 E describes the phantom of flow conditioner, and described flow conditioner has the inner core that is inserted in the shell and the composition surface on inner core and the shell, is used to prevent that inner core from discharging from shell.
Fig. 3 describes the cutaway view of the osmotic delivery system of the flow conditioner with Fig. 2 A.
The external accumulative total that Fig. 4 describes the activating agent that the osmotic delivery system of using Fig. 3 obtains discharges.
Detailed Description Of The Invention
With reference now to writing up the present invention as the several preferred embodiments that illustrate in the accompanying drawing.When describing preferred embodiment, set forth many details and fully understood of the present invention so that provide.Yet those skilled in the art can put into practice the present invention under the situation of not using some or all these details.In other situation, well-known features and/or processing step are not described in detail, so that unnecessarily make the present invention unclear.In addition, similar or identical reference number is used to represent shared or similar elements.
Fig. 2 A describes the phantom be used for from the flow conditioner 200 of the container delivery of active agent formulation of osmotic delivery system to 2E.With reference to figure 2A, flow conditioner 200 has the entrance side 201 of the active agent formulation in the container that is exposed to osmotic delivery system and is exposed to the outlet side 203 of the fluid environment that osmotic delivery system works therein.Typically, fluid environment is a liquid phase environment, that is to say, described fluid comprises water.Flow conditioner 200 comprises shell 202 and is inserted in the shell 202 and is generally columniform inner core 204.Between shell 202 and inner core 204, there is spiral helicine flow channel 206 to extend to outlet side 203 from the entrance side of flow conditioner 200.All of flow channel 206 or significant part can be helical form.Flow channel 206 is in flow conditioner 200 inside.Therefore, flow conditioner 200 forms barrier between the container of active agent formulation by flow channel 206 and osmotic delivery system.
In Fig. 2 A-2C, the outer surface 210 of inner core 204 cooperates with the inner surface 212 of shell 202.Flow channel 206 can be formed in the outer surface 210 of inner core 204, and shown in Fig. 2 A, perhaps flow channel 206 is formed in the inner surface 212 of shell 202, shown in Fig. 2 B.Perhaps, shown in Fig. 2 C, fluid passage 206 can comprise the first flow channel 206a in the outer surface 210 that is formed on inner core 204 and be formed on the second flow channel 206b in the inner surface 212 of shell 202, and wherein the first flow channel 206a and the second flow channel 206b are against each other or be communicated with.All of each flow channel 206a, 206b or significant part are helical form.Perhaps, shown in Fig. 2 D, the insert 214 that flows can be arranged between the inner surface 212 of the outer surface 210 of inner core 204 and shell 202, and the insert 214 that wherein flows provides flow channel 206.The insert 214 that flows can be for example coil pipe, and the distance between each circle of pipe plays the effect of flow channel 206.Perhaps, the insert 214 that flows can be the cylinder or the sleeve pipe of the hollow that wherein is formed with helical groove, and wherein helical groove plays the effect of flow channel 206.Flow channel 206 can have any required cross section, and the example comprises annular or D shape.The flow channel of in Fig. 2 A-2E, having represented D shape.The length of flow channel 206 depends on the structure of osmotic delivery system and required rate of release.Typically, ((spiral) length of flow channel 206 is 10 to 50mm.Typically, the effective cross-section diameter of flow channel 206 is 0.1 to 0.5mm.These scopes provide as an example, rather than are used to limit the present invention, except as otherwise noted.
With reference to figure 2A-2D, the maximum outside diameter of inner core 204 and the maximum inner diameter of shell 202 are selected, make between the inner surface 212 of the outer surface 210 of inner core 204 and shell 202, to form interference fit or sealing.This interference fit or sealing restriction preparation flow in the passage 206.This interference fit or sealing are enough to prevent that inner core 204 and/or mobile insert 214 are from shell 202 discharges.On the other hand, in Fig. 2 A-2C, the mating part on the surface 210,212 of inner core 204 and shell 202 can for example comprise respectively and be threaded, bonding connection, feature such as be welded to connect, so that in addition with respect to the fixing inner core 204 of shell 202.In Fig. 2 D, can between the part of interior and outer surface 214a, the 214b of the mobile insert 214 that cooperates with the surface 210,212 of inner core 204 and shell 202 respectively, form similar connection features.Fig. 2 E discloses the alternative approach that is used to prevent that inner core 204 from discharging from shell 202, and it is included in the outside shoulder 216 on the outer surface 210 of inner core 204, the inboard shoulder 218 butt/engagements on the inner surface 212 of itself and shell 202.Outlet side 203 discharges of inner core 204 have been prevented like this by flow conditioner 200.Butt/the mating surface of shoulder 216,218 can be flat or can be and phases down, as shown in Fig. 2 E.
Using butt/engagement shoulder 216,218 to prevent that inner core 204 is discharged to the fluid environment that osmotic delivery system works therein from shell 202 goes among the arbitrary embodiment shown in Fig. 2 A-2D.In addition, any feature of embodiment shown in Fig. 2 A-2E can be exchanged and combination, to produce the alternate embodiment of flow conditioner 200.For example, in Fig. 2 E, spiral helicine passage also can be arranged in the inner surface 212 of shell 202 as shown in Fig. 2 C.Perhaps, in Fig. 2 D, spiral helicine passage also can be arranged in the inner surface 212 of shell 202 and/or the outer surface 210 of inner core 204, respectively described in Fig. 2 A and 2B, wherein the flow channel 206 in the passage in shell 202 and/or the inner core 204 and the mobile insert 214 in abutting connection with or be communicated with.
With reference to figure 2A-2E, shell 202, inner core 204 and mobile insert 214 are preferably formed by inertia and biocompatible material.The example of inert biocompatible material includes but not limited to non-reactive polymer and metal for example titanium, rustless steel, platinum and their alloy and cochrome.When can be used for wherein wishing in active agent formulation being delivered to the fluid environment that osmotic delivery system works therein, non-reactive polymer avoids the interactional situation between active agent formulation and the metal material.The example of the non-reactive polymer that is fit to includes but not limited to PAEK for example polyether-ether-ketone and polyaryletheretherketone, ultra-high molecular weight polyethylene, fluorizated ethylene-propylene, polymethylpentene and liquid crystal polymer.Preferably, at least following surface is not by making or scribble described material to the material that active agent formulation has an illeffects, and described surface is included in the surface of the shell 202, inner core 204 and the mobile insert 214 that are exposed to active agent formulation when active agent formulation flows through flow channel 206.In a preferred embodiment, above-mentioned surface is made by inert and biocompatible nonmetallic materials.This nonmetallic materials can be non-reactive polymer, and the example provides above-mentioned.
Can select length, shape of cross section and the circulating area of flow channel 206, make the average linear velocity of active agent formulation by flow channel 206 than material because diffusion or infiltration are higher from the linear average linear velocity that inwardly flows into of fluid environment that osmotic delivery system works therein.Can have decay like this or relax the effect of back-diffusion,, then may pollute the active agent formulation in the osmotic delivery system if describedly back-diffusion is not controlled.Can regulate the rate of release of active agent formulation by the geometry of regulating flow channel 206, as described below.
The convective flow of activating agent by flow channel 206 is by the surfactant concentration decision in the active agent formulation in the container of the pump rate of osmotic delivery system and osmotic delivery system.Convective flow can be expressed as:
Qca=(Q)(Ca) (1)
Wherein Qca is the convective transport that is expressed as mg/ days activating agent (beneficial), and Q is expressed as cm
3The overall convective transport and the Ca of the active agent formulation in/sky are expressed as mg/cm
3The container of osmotic delivery system in active agent formulation in the concentration of activating agent.
The diffusional flow that activating agent leaves flow channel 206 is surfactant concentration and the shape of cross section of diffusibility and flow channel 206 and the function of length.Diffusional flow can be expressed as:
Wherein Qda is the diffusion transhipment that is expressed as mg/ days activating agent, and D is expressed as cm
2The diffusibility of passing through flow channel 206 in/sky, r is the effective internal diameter that is expressed as the flow channel 206 of cm, Δ Ca is expressed as mg/cm
3The osmotic delivery system container in the surfactant concentration of active agent formulation and the surfactant concentration in the fluid environment in delivery orifice 205 outsides of flow conditioner 200 poor, and L is (spiral) length that is expressed as the flow channel 206 of cm.
Usually, the surfactant concentration in the osmotic delivery system in the active agent formulation is more much bigger than the surfactant concentration in the fluid environment of using, and makes that described poor Δ Ca can be near the surfactant concentration Ca in the active agent formulation in the osmotic delivery system.Therefore:
Usually the convective flow of the diffusion flux specific activity agent of expectation maintenance activating agent is much smaller.This can be expressed as follows:
Equation (4) expression relative diffusion flux reduces with the increase of volume flow velocity and path-length, increases with the increase of diffusibility and channel radius, and irrelevant with surfactant concentration.
Wherein flow channel 206 is can approximate representation as follows at the diffusion flux of the water at osmotic delivery system split shed place:
Wherein Co is expressed as mg/cm
3The CONCENTRATION DISTRIBUTION of water, Q is expressed as mg/ days mass velocity, L is the length that is expressed as the flow channel 206 of cm, Dw is expressed as cm
2The water in/sky is expressed as cm by the diffusibility and the A of material in the flow channel 206
2The cross-sectional area of flow channel 206.
The fluid dynamic pressure drop of crossing over delivery orifice can be calculated as follows:
Wherein Q is expressed as mg/ days mass velocity, and L is the helical flow passage length that is expressed as cm, and μ is the viscosity of preparation, and r is the effective internal diameter that is expressed as the flow channel of cm.
Fig. 3 represents to comprise the osmotic delivery system 300 of flow conditioner 200.Although osmotic delivery system 300 is expressed as the flow conditioner 200 with Fig. 2 A, apparent, any flow conditioner 200 shown in Fig. 2 A-2E can be used for osmotic delivery system 300.Osmotic delivery system 300 comprises container 302, and its size can be and makes and it can be implanted in vivo.Container 302 has open end 304,306.Flow conditioner 200 is inserted in the open end 304.Semipermeable plug 308 is inserted in the open end 306.
Semipermeable plug 308 is fluid flow films in the container 302 of the fluid environment that works therein from osmotic delivery system of control.Semipermeable plug 308 allows to enter container 302 from the fluid of fluid environment.Because the semipermeability character of semipermeable plug 308 is prevented from by semipermeable plug 308 flow containers 302 compositions in the container 302.Semipermeable plug 308 can partially or completely be inserted in the open end 306.In the previous case, semipermeable plug 308 can comprise the end portion 308a of expansion, and it works as the stopping element that the end with container 302 meshes.The outer surface 308b of semipermeable plug 308 can have projection or the burr 308c with inner surface 310 engagement of container 302, thereby is locked in semipermeable plug 308 on the container 302 and allows to form sealing between container 302 and semipermeable plug 308.Container 302 can also comprise undercutting, is used to accept the projection 308c on the semipermeable plug 308.The semipermeable materials that is used for semipermeable plug 308 is the material that can meet the shape of container 302 and can adhere to the inner surface 310 of container 302 when moistening.Typically, these materials are polymeric materials, and it can require to select according to pump rate and system configuration.The example of the semipermeable materials that is fit to includes but not limited to for example for example polyurethane and polyamide, polyphenylene ether-polyamide copolymer, thermoplastic copolyester or the like of hydroxyethyl meth acrylate (HEMA) and elastomeric material of plastifying cellulosic material, enhanced polymethyl methacrylate (PMMA).Common optimization polyurethane.
In container 302, limit two chambers 312,314.Piston that is for example slided by spacer 316 in chamber 312,314 or flexible membrane are separated, and described spacer is configured to cooperate container 302 in and produces sealing and contact and be used in container 302 longitudinally mobile or be out of shape.Preferably, spacer 316 is formed by the elastomeric material of impermeability.For example, spacer 316 can and can comprise the annular projection 316a that forms sealing with the inner surface 310 of container 302 for the sliding plunger made by the impermeability elastomeric material.Osmotic engine material 318 is arranged in the chamber 314 with semipermeable plug 308 adjacency, and active agent formulation is arranged in the chamber 312 with flow conditioner 200 adjacency.Spacer 316 makes active agent formulation 320 and the environment liquid separation that is allowed to enter by semipermeable plug 308 container 302, make in use, when steady-flow, active agent formulation 320 is to be discharged from by flow channel 206 by the suitable speed of the speed of semipermeable plug 308 inflow containers 302 from fluid environment with fluid.
Osmotic engine material 318 can be as directed tablet form.Can use one or more this tablets.Perhaps, osmotic engine material 318 can have other shape, quality, density and denseness.For example, osmotic engine material 318 can be powder or particle form.Osmotic engine material 318 can comprise osmopolymer (osmopolymer).Osmopolymer is to absorb aqueous fluid for example water and biological fluid and expand when sucking aqueous fluid or be expanded to poised state and keep signal portion and be absorbed fluidic hydrophilic polymer.Osmopolymers swell or be expanded to very high degree, being usually expressed as 2 to 50 times of volumes increases.Osmopolymer is can yes or no crosslinked.Preferred osmopolymer is slight cross-linked hydrophilic polymer, this crosslinked be by covalent bond or ionic bond or the residual crystal region after expanding forms.Osmopolymer can be plant, animal or synthetic source.Be suitable for the osmopolymer of osmotic engine material 318 or the example of hydrophilic polymer and include but not limited to that molecular weight is 30,000 to 5,000,000 poly-(hydroxy alkyl methacrylate); Molecular weight is 10,000 to 360,000 polyvinylpyrrolidone (PVP); Anionic and cationic hydrogel; Compound polyelectrolyte; The low acetate root is residual, be 200 to 30,000 polyvinyl alcohol with Biformyl, formaldehyde or glutaraldehyde cross-linking and the degree of polymerization, methylcellulose, crosslinked agar and the mixture of carboxymethyl cellulose; The mixture of hydroxypropyl emthylcellulose and sodium carboxymethyl cellulose; The mixture of Cellulose ethyl hydroxypropyl ether and sanlose; Sodium carboxymethyl cellulose; Carboxymethyl-cellulose potassium salt; By water-fast, the expandable copolymer of water that the dispersion of the finely divided copolymer of maleic anhydride and styrene, ethylene, propylene, butylene or isobutene. forms, every mole of maleic anhydride of every kind of copolymer has 0.001 to about 0.5 mole saturated cross-linking agent; The water swellable polymer of N-vinyl lactam; Polyethylene glycol oxide-polypropylene oxide gel; Polyoxybutylene-polyethylene block copolymer gel; Tragon; Carbopol gel; Polyester gel; Polyurea gel; The polyethers gel; Polyamide gels; Poly-cellulose gel; Poly-gummy gel (polygumgel); Absorb and the glassy hydrogel of adsorption and permeation and reduce the initial exsiccant hydrogel of the water of its vitrification point.Other example of osmopolymer comprises the polymer that forms hydrogel, for example: CARBOPOL
, tart carboxyl polymer, a kind of polymerizing acrylic acid thing and crosslinked with polyene propyl group sucrose has another name called polyacrylic acid and carbopol, and molecular weight is 250,000 to 4,000,000; CYNAMER
Polyacrylamide; The expandable indenes of crosslinked water-maleic anhydride polymer; Molecular weight is 80,000 to 200,000 GOOD-RITE
Polyacrylic acid; Molecular weight is 100,000 to 5,000,000 and more high-molecular weight POLYOX
Polyethylene oxide polymer; Starch graft copolymer; The AQUA KEEPS that forms by the glucose unit of condensation
Acrylate polymer polysaccharide, for example crosslinked polysaccharide (polygluran) of diester; Or the like.Except osmopolymer or replace osmopolymer, osmotic engine material 318 can also comprise penetrating agent (osmagent).Penetrating agent comprises the inorganic and organic compound that shows the osmotic pressure gradient of striding semipermeable wall with respect to external fluid.Osmagents imbibe fluid in osmosis system, thereby utilize fluid to promote preparation, be used to send and pass through flow conditioner.Penetrating agent has another name called osmotically active chemical compound or solute.The example that can be used for the penetrating agent of osmotic engine material 318 comprises magnesium sulfate, magnesium chloride, sodium chloride, potassium sulfate, sodium sulfate, lithium sulfate, potassium hydrogen phosphate, mannitol, carbamide, inositol, Magnesium succinate, tartaric acid, carbohydrate for example cottonseed sugar (raffmose), sucrose, glucose, lactose, sorbitol and composition thereof.
Active agent formulation 320 can comprise one or more activating agents. activating agent can be the material of any physiology or pharmacological activity, particularly becomes known for being delivered to those of human body or animal body, for example medicine, vitamin, nutrient etc.Can include but not limited to act on infectious disease by the activating agent that flow conditioner 200 usefulness osmotic delivery system 300 are sent, chronic pain, diabetes, peripheral nervous, adrenoreceptor, cholinoceptor, skeletal muscle, cardiovascular system, smooth muscle, blood circulation, the synapse position, the neural effector bonding station, endocrine and hormone system, immune system, reproductive system, skeletal system, autocrine system, digestion and Excretory system, histamine system and central nervous system.The reagent that is fit to can be selected from for example synthetic analogues of protein, enzyme, hormone, polynucleotide, nucleoprotein, polysaccharide, glycoprotein, lipoprotein, polypeptide, steroidal, analgesic, local anesthetic, antibiotic, antiinflammatory usefulness corticosteroid, eye medicinal and these materials.Preferred activating agent comprises macromole (protein and peptide) and highly effective activating agent.Activating agent can be used as number of chemical and physical form exists, for example solid, liquid and slurry.Except one or more activating agents, preparation 320 can randomly comprise pharmaceutically acceptable carrier and/or other composition, for example antioxidant, stabilizing agent, buffer agent and penetration enhancers.
The material that is used for container 302 should be fully hard, do not change its size or shape so that stand the expansion of osmotic engine material 318.In addition, described material should guarantee under can be in the implantation process not suffered stress of container 302 or owing to seepage, crack under the stress of the pressure that produces in the operating process, break or be out of shape.Container 302 can be formed by inert, biocompatible, natural or synthetic material known in the art.The material of container 302 can be or not be biological erodible.Biological erodible material is partly dissolved at least, degrades in the fluid environment of its application or otherwise corrosion.Preferably, the material of container 302 is not biological erodible.Usually, the material of preferred container 302 is to be applicable to human those that implant.Preferably, the material right and wrong of container 302 are infiltrative, and particularly the preparation stability in container 302 is to the fluid environment of using when responsive.The example that is suitable for the material of container 302 comprises non-reactive polymer or biocompatible metals or alloy.The example that is used for the non-reactive polymer of container 302 includes but not limited to for example acrylonitrile-butadiene-styrene terpolymer of acrylonitrile polymer; Halogenated polymer is politef, polychlorotrifluoroethylene, tetrafluoroethene and hexafluoropropylene copolymer for example; Polyimides; Polysulfones; Merlon; Polyethylene; Polypropylene; Polrvinyl chloride-acrylic copolymer; Merlon-acrylonitrile-butadiene-styrene (ABS); And polystyrene.The example of the metallic alloy of container includes but not limited to rustless steel, titanium, platinum, tantalum, gold and their alloy, and the rustless steel of gold-plated ferroalloy, platinized ferroalloy, cochrome and titanium nitride coating.Use and wherein chemosensitive application in the body of preparation to implantation position for the decisive application of size, high payload capability, long duration, preferred container 302 is by titanium or have greater than the titanium alloy of 60% (usually greater than 85%) titanium and make.
Can select the diameter of flow conditioner 200, make flow conditioner 200 can be press fit in the open end 304 of container 302.Also might on the inner surface 310 of the outer surface 220 of shell 202 and container 302, comprise for example screw thread of feature, be used for respect to the fixing flow conditioner 200 of container 302.
Following examples are used to illustrate the present invention, should not be seen as restriction the present invention, unless explanation is arranged herein in addition.
Be used for the treatment of for example following assembled of osmotic delivery system of the interferon-ω of hepatitis C (IFN-ω) illustrated in fig. 3 comprising: (i) make and have at its end the container of undercutting by implanting the level titanium alloy, the osmotic engine material that (ii) comprises two cylindrical tablet, each tablet mainly comprises the sodium chloride salt with cellulose and polyvidone binding agent, (iii) piston, (iv) make and have the semipermeable plug of the maintenance burr that cooperates with undercutting in the container by polyurethane, (the flow conditioner that v) has the spiral type inner flow passage of D shape cross section, diameter 0.25mm, helix length is 35mm and the (suspension preparation that vi) comprises the granular preparation that is suspended in the IFN-ω in the non-water vehicle.
Suspension preparation with the vessel filling 150 μ L of above-mentioned several osmotic delivery system.The semipermeable plug ends of osmotic delivery system is placed the cuvette that is full of phosphate buffer (PBS), the flow modulator ends of osmotic delivery system is placed the cuvette that is full of moisture release medium.System is stored or insulation at 5 ℃ and 30 ℃ respectively.At specific time point, the solution that release medium can be removed and more renewed.Use reversed phase high-performance liquid chromatography (RP-HPLC) that the release medium of sampling is analyzed active agent content.The external accumulative total of IFN-ω that Fig. 4 was illustrated in June discharges.
The present invention can provide following advantage.Two-piece flow modulator makes the design of flow conditioner have motility and allows the manufacturability of flow conditioner.Shell and container are not whole, and make it possible to check before being inserted into flow conditioner in the container passage of flow conditioner.Two-piece flow modulator makes that the other mechanical force to passage minimizes in the process that flow conditioner is inserted in the container.Two-piece flow modulator allows to optimize by the passage on change inner core or the mobile insert motility of flow channel size in the shared trocar sheath of maintenance.
Although described embodiment with reference to limited embodiment, those skilled in the art should be appreciated that after understanding the present invention, can design other embodiment and do not break away from scope of the present invention disclosed herein.Therefore, scope of the present invention is only by the claim restriction of enclosing.
Claims (17)
1. be used for the implantable osmotic delivery system of active agent formulation, comprise:
The container of making by impermeable material;
First Room that comprises the osmotic engine material in container;
Second Room that comprises active agent formulation in container;
Be arranged in the container and the spacer that can move therein, described spacer limits first Room that comprises the osmotic engine material and second Room that comprises active agent formulation;
Be arranged on container first end, with the semipermeable plug of the first Room adjacency; With
Be arranged on container second end, with the flow conditioner of the second Room adjacency, described flow conditioner comprises:
Be positioned at the shell in the opening of second end of container of osmotic delivery system, described shell comprises inner surface;
Be inserted into the inner core in the described shell, described inner core comprises outer surface; With
The helical form flow channel that limits between the outer surface of the inner surface of described shell and inner core, described flow channel is suitable for the container delivery of active agent formulation from osmotic delivery system.
2. the implantable osmotic delivery system of claim 1, wherein flow channel is formed on the outer surface of the inner core that cooperates with the inner surface of shell.
3. the implantable osmotic delivery system of claim 1, wherein flow channel is formed on the inner surface of the shell that cooperates with the outer surface of inner core.
4. the implantable osmotic delivery system of claim 1 comprises the mobile insert that is arranged between shell and the inner core in addition, wherein forms flow channel in described mobile insert.
5. the implantable osmotic delivery system of claim 4, wherein shell, inner core and mobile insert are formed by inert material.
6. the implantable osmotic delivery system of claim 5, wherein inert material is nonmetallic materials.
7. the implantable osmotic delivery system of claim 1, wherein shell and inner core are formed by inert material.
8. the implantable osmotic delivery system of claim 7, wherein inert material is nonmetallic materials.
9. the implantable osmotic delivery system of claim 8, wherein said material is polyether-ether-ketone, polyaryletheretherketone, ultra-high molecular weight polyethylene, fluorizated ethylene-propylene, polymethylpentene or liquid crystal polymer.
10. the implantable osmotic delivery system of claim 1, wherein body seal meshes described inner core.
11. the implantable osmotic delivery system of claim 1, wherein said inner core comprise outside shoulder, described shell comprises inboard shoulder, and wherein said outside shoulder and the engagement of inboard shoulder are to prevent that in use inner core is discharged from shell.
12. the implantable osmotic delivery system of claim 1, wherein the length of flow channel is 10 to 50mm.
13. the implantable osmotic delivery system of claim 1, wherein the effective cross-section diameter of flow channel is 0.1 to 0.5mm.
14. the implantable osmotic delivery system of claim 1, wherein flow conditioner is press fit in second end of container.
15. each implantable osmotic delivery system of claim 1-14, wherein active agent formulation is selected from interferon-ω.
16. each implantable osmotic delivery system of claim 1-14, the material of wherein said container is selected from titanium or titanium alloy.
17. each implantable osmotic delivery system of claim 1-14, wherein said spacer is piston slidably.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80945106P | 2006-05-30 | 2006-05-30 | |
US60/809,451 | 2006-05-30 | ||
PCT/US2007/069990 WO2007140416A2 (en) | 2006-05-30 | 2007-05-30 | Two-piece, internal-channel osmotic delivery system flow modulator |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101453982A CN101453982A (en) | 2009-06-10 |
CN101453982B true CN101453982B (en) | 2011-05-04 |
Family
ID=38617914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007800187567A Active CN101453982B (en) | 2006-05-30 | 2007-05-30 | Two-piece, internal-channel osmotic delivery system flow modulator |
Country Status (16)
Country | Link |
---|---|
US (8) | US8052996B2 (en) |
EP (1) | EP2020990B1 (en) |
JP (1) | JP5143131B2 (en) |
KR (1) | KR101106510B1 (en) |
CN (1) | CN101453982B (en) |
AT (1) | ATE481963T1 (en) |
AU (1) | AU2007266475B2 (en) |
CA (1) | CA2651855C (en) |
DE (1) | DE602007009377D1 (en) |
DK (1) | DK2020990T3 (en) |
ES (1) | ES2351527T3 (en) |
HK (1) | HK1129203A1 (en) |
IL (1) | IL194746A (en) |
MX (1) | MX2008014870A (en) |
NZ (1) | NZ572003A (en) |
WO (1) | WO2007140416A2 (en) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY125870A (en) * | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system flow modulator apparatus and method |
US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
US7919109B2 (en) | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
JP4248236B2 (en) * | 2000-11-29 | 2009-04-02 | デュレクト コーポレイション | Device and method for controlling delivery from a drug delivery device |
KR20050026402A (en) * | 2002-06-17 | 2005-03-15 | 알자 코포레이션 | Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
CA2520610A1 (en) * | 2003-03-31 | 2004-10-21 | Alza Corporation | Osmotic pump with means for dissipating internal pressure |
TW200509999A (en) * | 2003-03-31 | 2005-03-16 | Alza Corp | Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems |
US7407499B2 (en) * | 2003-10-31 | 2008-08-05 | Intarcia Therapeutics, Inc. | Osmotic pump with self-retaining, fast-start membrane plug |
WO2005046639A2 (en) * | 2003-11-06 | 2005-05-26 | Alza Corporation | Modular imbibition rate reducer for use with implantable osmotic pump |
EP1877077A2 (en) * | 2005-02-03 | 2008-01-16 | Intarcia Therapeutics, Inc. | An implantable interferon-containing device |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US7959938B2 (en) * | 2005-03-15 | 2011-06-14 | Intarcia Therapeutics, Inc. | Polyoxaester suspending vehicles for use with implantable delivery systems |
JP5143131B2 (en) | 2006-05-30 | 2013-02-13 | インターシア セラピューティクス,インコーポレイティド | Two-piece internal channel flow modulator for osmotic delivery system |
PL2359808T3 (en) * | 2006-08-09 | 2013-10-31 | Intarcia Therapeutics Inc | Osmotic delivery systems and piston assemblies |
CA2683610C (en) | 2007-04-23 | 2013-01-08 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
DK2240155T3 (en) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Devices, formulations and methods for the delivery of several beneficial agents |
CN102281865B (en) * | 2008-10-15 | 2017-04-05 | 精达制药公司 | Highly enriched drug particles, preparation, suspensoid and its application |
BRPI1006755A2 (en) * | 2009-04-07 | 2019-03-26 | Koninl Philips Electronics Nv | drug delivery device |
KR101823699B1 (en) | 2009-09-28 | 2018-01-30 | 인타르시아 세라퓨틱스 인코포레이티드 | Rapid establishment and/or termination of substantial steady-state drug delivery |
US9017310B2 (en) | 2009-10-08 | 2015-04-28 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including microneedles |
US8882748B2 (en) | 2009-10-08 | 2014-11-11 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including chemical permeation enhancers |
US9014799B2 (en) | 2009-10-08 | 2015-04-21 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including electrically-actuated permeation enhancement |
US20110301555A1 (en) * | 2010-06-03 | 2011-12-08 | Gonzalez-Zugasti Javier P | Porous matrix drug core for lacrimal insert device |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
KR101248035B1 (en) | 2011-08-25 | 2013-04-09 | 강성삼 | Safty brake system for automatic transmission car |
US20130090633A1 (en) * | 2011-10-07 | 2013-04-11 | University Of Southern California | Osmotic patch pump |
US9046085B2 (en) * | 2012-03-14 | 2015-06-02 | Eden Medical, Inc. | Miniature pumps |
US20140088345A1 (en) * | 2012-09-27 | 2014-03-27 | Palo Alto Research Center Incorporated | Single channel, multiple drug delivery device and methods |
US9005108B2 (en) * | 2012-09-27 | 2015-04-14 | Palo Alto Research Center Incorporated | Multiple reservoir drug delivery device and methods |
US9999720B2 (en) | 2012-09-27 | 2018-06-19 | Palo Alto Research Center Incorporated | Drug reconstitution and delivery device and methods |
WO2014102741A2 (en) * | 2012-12-28 | 2014-07-03 | University Of The Witwatersrand, Johannesburg | Pharmaceutical dosage form |
US9744341B2 (en) | 2013-01-15 | 2017-08-29 | Palo Alto Research Center Incorporated | Devices and methods for intraluminal retention and drug delivery |
US9297083B2 (en) | 2013-12-16 | 2016-03-29 | Palo Alto Research Center Incorporated | Electrolytic gas generating devices, actuators, and methods |
WO2015116646A1 (en) * | 2014-01-28 | 2015-08-06 | Mccoy Enterprises, Llc | Collagen permeated medical implants |
US10278675B2 (en) | 2014-07-31 | 2019-05-07 | Palo Alto Research Center Incorporated | Implantable estrus detection devices, systems, and methods |
US9801660B2 (en) | 2014-07-31 | 2017-10-31 | Palo Alto Research Center Incorporated | Implantable fluid delivery devices, systems, and methods |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US9903503B2 (en) * | 2014-11-26 | 2018-02-27 | B/E Aerospace, Inc. | Aircraft water heating tank air vent valve |
MX2017015504A (en) | 2015-06-03 | 2018-05-15 | Intarcia Therapeutics Inc | Implant placement and removal systems. |
WO2017079467A1 (en) | 2015-11-05 | 2017-05-11 | The General Hospital Corporation | Intrathecal delivery of nucleic acid sequences encoding abcd1 for treatment of adrenomyeloneuropathy |
AU2017268161B2 (en) | 2016-05-16 | 2020-03-12 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
US10406336B2 (en) | 2016-08-03 | 2019-09-10 | Neil S. Davey | Adjustable rate drug delivery implantable device |
WO2018075901A1 (en) | 2016-10-20 | 2018-04-26 | Peptron, Inc. | Methods of delivering a neuroprotective polypeptide to the central nervous system |
AU2018206539A1 (en) | 2017-01-03 | 2019-07-18 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
EP3592376A1 (en) | 2017-03-08 | 2020-01-15 | Intarcia Therapeutics, Inc | Apparatus and methods for administration of a nauseogenic compound from a drug delivery device |
USD933219S1 (en) | 2018-07-13 | 2021-10-12 | Intarcia Therapeutics, Inc. | Implant removal tool and assembly |
CN113195524A (en) | 2018-10-11 | 2021-07-30 | 因塔西亚治疗公司 | Human amylin analog polypeptides and methods of use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6524305B1 (en) * | 1997-07-25 | 2003-02-25 | Alza Corporation | Osmotic delivery system flow modulator apparatus and method |
Family Cites Families (509)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR640907A (en) | 1927-06-25 | 1928-07-24 | Automatic flow limiter | |
US2168437A (en) | 1935-04-10 | 1939-08-08 | Kenneth O Buercklin | Injection device |
US2110208A (en) | 1937-02-12 | 1938-03-08 | U S Standard Products Company | Antigen preparations |
US3025991A (en) | 1960-05-23 | 1962-03-20 | Carron Products Co | Bottle stopper |
GB1049104A (en) | 1963-05-11 | 1966-11-23 | Prodotti Antibiotici Spa | Pharmaceutical compositions for oral or parenteral administration comprising tetracycline antibiotics |
US3122162A (en) | 1963-06-20 | 1964-02-25 | Asa D Sands | Flow control device |
US3632768A (en) | 1969-10-02 | 1972-01-04 | Upjohn Co | Therapeutic composition and method for treating infections with actinospectacin |
US3625214A (en) | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
US4034756A (en) | 1971-01-13 | 1977-07-12 | Alza Corporation | Osmotically driven fluid dispenser |
US3732865A (en) | 1971-01-13 | 1973-05-15 | Alza Corp | Osmotic dispenser |
US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
BE795516A (en) | 1972-02-17 | 1973-08-16 | Ciba Geigy | PREPARATIONS OF OILY AND INJECTABLE PEPTIDES AND PROCESS FOR THEIR PREPARATION |
US3797492A (en) | 1972-12-27 | 1974-03-19 | Alza Corp | Device for dispensing product with directional guidance member |
US3995632A (en) | 1973-05-04 | 1976-12-07 | Alza Corporation | Osmotic dispenser |
DE2528516A1 (en) | 1974-07-05 | 1976-01-22 | Sandoz Ag | NEW GALENIC PREPARATION |
US3987790A (en) | 1975-10-01 | 1976-10-26 | Alza Corporation | Osmotically driven fluid dispenser |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4078060A (en) | 1976-05-10 | 1978-03-07 | Richardson-Merrell Inc. | Method of inducing an estrogenic response |
US4111202A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
US4111201A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for delivering selected beneficial agents having varying degrees of solubility |
US4243030A (en) | 1978-08-18 | 1981-01-06 | Massachusetts Institute Of Technology | Implantable programmed microinfusion apparatus |
US4305927A (en) | 1979-02-05 | 1981-12-15 | Alza Corporation | Method for the management of intraocular pressure |
US4373527B1 (en) | 1979-04-27 | 1995-06-27 | Univ Johns Hopkins | Implantable programmable medication infusion system |
US4310516A (en) | 1980-02-01 | 1982-01-12 | Block Drug Company Inc. | Cosmetic and pharmaceutical vehicle thickened with solid emulsifier |
AU546785B2 (en) | 1980-07-23 | 1985-09-19 | Commonwealth Of Australia, The | Open-loop controlled infusion of diabetics |
US4350271A (en) | 1980-08-22 | 1982-09-21 | Alza Corporation | Water absorbing fluid dispenser |
US4376118A (en) | 1980-10-06 | 1983-03-08 | Miles Laboratories, Inc. | Stable nonaqueous solution of tetracycline salt |
US4340054A (en) | 1980-12-29 | 1982-07-20 | Alza Corporation | Dispenser for delivering fluids and solids |
US4455145A (en) | 1981-07-10 | 1984-06-19 | Alza Corporation | Dispensing device with internal drive |
AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
EP0079143A3 (en) | 1981-10-20 | 1984-11-21 | Adnovum Ag | Pseudoplastic gel transfer |
EP0080879B1 (en) | 1981-11-28 | 1986-10-01 | Sunstar Kabushiki Kaisha | Pharmaceutical composition containing interferon in stable state |
US5004689A (en) | 1982-02-22 | 1991-04-02 | Biogen, Massachusetts | DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4455143A (en) | 1982-03-22 | 1984-06-19 | Alza Corporation | Osmotic device for dispensing two different medications |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
DE3220116A1 (en) | 1982-05-28 | 1983-12-01 | Dr. Karl Thomae Gmbh, 7950 Biberach | MICROBIOLOGICALLY MANUFACTURED (ALPHA) AND SS INTERFERONES, DNA SEQUENCES CODING FOR THESE INTERFERONES, MICROORGANISMS CONTAINING THIS GENETIC INFORMATION, AND METHOD FOR THE PRODUCTION THEREOF |
US4753651A (en) | 1982-08-30 | 1988-06-28 | Alza Corporation | Self-driven pump |
US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
US4552561A (en) | 1982-12-23 | 1985-11-12 | Alza Corporation | Body mounted pump housing and pump assembly employing the same |
US4673405A (en) | 1983-03-04 | 1987-06-16 | Alza Corporation | Osmotic system with instant drug availability |
US4639244A (en) | 1983-05-03 | 1987-01-27 | Nabil I. Rizk | Implantable electrophoretic pump for ionic drugs and associated methods |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
DE3320583A1 (en) | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW GALENIC PREPARATION FORMS OF ORAL ANTIDIABETICS AND METHOD FOR THE PRODUCTION THEREOF |
JPS6058915A (en) | 1983-09-12 | 1985-04-05 | Fujisawa Pharmaceut Co Ltd | Lipid microcapsule preparation containing medicament |
US4594108A (en) | 1983-09-19 | 1986-06-10 | The Dow Chemical Company | Highly pseudoplastic polymer solutions |
US5385738A (en) | 1983-10-14 | 1995-01-31 | Sumitomo Pharmaceuticals Company, Ltd. | Sustained-release injection |
US4855238A (en) | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
MX9203641A (en) | 1983-12-16 | 1992-07-01 | Genentech Inc | RECOMBINANT GAMMA INTERFERONS THAT HAVE IMPROVED STABILITY AND BIOTECHNOLOGICAL METHODS FOR THEIR OBTAINING. |
US4851228A (en) | 1984-06-20 | 1989-07-25 | Merck & Co., Inc. | Multiparticulate controlled porosity osmotic |
US5120832A (en) | 1984-08-27 | 1992-06-09 | Genentech, Inc. | Distinct family of human leukocyte interferons |
US5231176A (en) | 1984-08-27 | 1993-07-27 | Genentech, Inc. | Distinct family DNA encoding of human leukocyte interferons |
US4927687A (en) | 1984-10-01 | 1990-05-22 | Biotek, Inc. | Sustained release transdermal drug delivery composition |
US5411951A (en) | 1984-10-04 | 1995-05-02 | Monsanto Company | Prolonged release of biologically active somatotropin |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
FI90990C (en) | 1984-12-18 | 1994-04-25 | Boehringer Ingelheim Int | Recombinant DNA molecule, transformed host organism, and method for producing interferon |
US4655462A (en) | 1985-01-07 | 1987-04-07 | Peter J. Balsells | Canted coiled spring and seal |
JPS61189230A (en) | 1985-02-19 | 1986-08-22 | Nippon Kayaku Co Ltd | Etoposide preparation |
US4609374A (en) | 1985-04-22 | 1986-09-02 | Alza Corporation | Osmotic device comprising means for governing initial time of agent release therefrom |
DE3685996T2 (en) | 1985-06-11 | 1993-01-14 | Ciba Geigy Ag | HYBRID INTERFERONE. |
US4845196A (en) | 1985-06-24 | 1989-07-04 | G. D. Searle & Co. | Modified interferon gammas |
US4847079A (en) | 1985-07-29 | 1989-07-11 | Schering Corporation | Biologically stable interferon compositions comprising thimerosal |
DE3607835A1 (en) | 1986-03-10 | 1987-09-24 | Boehringer Ingelheim Int | HYBRID INTERFERONS, THEIR USE AS MEDICINAL PRODUCTS AND AS INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF ANTIBODIES AND THE USE THEREOF AND METHOD FOR THEIR PRODUCTION |
US4865845A (en) | 1986-03-21 | 1989-09-12 | Alza Corporation | Release rate adjustment of osmotic or diffusional delivery devices |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US6849708B1 (en) | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US7138486B2 (en) | 1986-05-05 | 2006-11-21 | The General Hospital Corporation | Insulinotropic hormone derivatives and uses thereof |
US4755180A (en) | 1986-06-16 | 1988-07-05 | Alza Corporation | Dosage form comprising solubility regulating member |
DE3636123A1 (en) | 1986-10-23 | 1988-05-05 | Rentschler Arzneimittel | ORAL ADMINISTRATIVE PREPARATIONS CONTAINING SINGLE DOSE FROM 10 TO 240 MG DIHYDROPYRIDINE |
CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
ZA878295B (en) | 1986-11-06 | 1988-05-03 | Amarillo Cell Culture Co. Inc. | Treatment of immuno-resistant disease |
DE3642096A1 (en) | 1986-12-10 | 1988-06-16 | Boehringer Ingelheim Int | HORSE (GAMMA) INTERFERON |
US5371089A (en) | 1987-02-26 | 1994-12-06 | Senetek, Plc | Method and composition for ameliorating the adverse effects of aging |
US5278151A (en) | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
JPH0720866B2 (en) | 1987-05-15 | 1995-03-08 | 三生製薬株式会社 | Transdermal preparation containing eperisone or tolperisone or their salts |
US4940465A (en) | 1987-05-27 | 1990-07-10 | Felix Theeuwes | Dispenser comprising displaceable matrix with solid state properties |
US4892778A (en) | 1987-05-27 | 1990-01-09 | Alza Corporation | Juxtaposed laminated arrangement |
US4874388A (en) | 1987-06-25 | 1989-10-17 | Alza Corporation | Multi-layer delivery system |
US5938654A (en) | 1987-06-25 | 1999-08-17 | Alza Corporation | Osmotic device for delayed delivery of agent |
US5023088A (en) | 1987-06-25 | 1991-06-11 | Alza Corporation | Multi-unit delivery system |
US4915949A (en) | 1987-07-13 | 1990-04-10 | Alza Corporation | Dispenser with movable matrix comprising a plurality of tiny pills |
US4915954A (en) | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering a drug at two different rates |
US5756450A (en) | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
US4886668A (en) | 1987-09-24 | 1989-12-12 | Merck & Co., Inc. | Multiparticulate controlled porosity osmotic pump |
US4917895A (en) | 1987-11-02 | 1990-04-17 | Alza Corporation | Transdermal drug delivery device |
JPH0740268Y2 (en) * | 1988-04-07 | 1995-09-13 | 株式会社東海理化電機製作所 | Sliding contact switch |
US4964204A (en) | 1988-04-25 | 1990-10-23 | Peter J. Balsells | Method for making a garter-type axially-resilient coil spring |
US4961253A (en) | 1988-04-25 | 1990-10-09 | Peter J. Balsells | Manufacturing method for canted-coil spring with turn angle and seal |
US5160122A (en) | 1990-03-20 | 1992-11-03 | Peter J. Balsells | Coil spring with an elastomer having a hollow coil cross section |
US4907788A (en) | 1988-04-25 | 1990-03-13 | Peter J. Balsells | Dual concentric canted-coil spring apparatus |
US4974821A (en) | 1988-04-25 | 1990-12-04 | Peter J. Balsells | Canted-coil spring with major axis radial loading |
US5108078A (en) | 1988-04-25 | 1992-04-28 | Peter J. Balsells | Canted-coil spring loaded while in a cavity |
US4915366A (en) | 1988-04-25 | 1990-04-10 | Peter J. Balsells | Outside back angle canted coil spring |
US4876781A (en) | 1988-04-25 | 1989-10-31 | Peter J. Balsells | Method of making a garter-type axially resilient coiled spring |
US5079388A (en) | 1989-12-01 | 1992-01-07 | Peter J. Balsells | Gasket for sealing electromagnetic waves |
US4893795A (en) | 1988-08-15 | 1990-01-16 | Peter J. Balsells | Radially loaded canted coiled spring with turn angle |
US5072070A (en) | 1989-12-01 | 1991-12-10 | Peter J. Balsells | Device for sealing electromagnetic waves |
US4934666A (en) | 1988-04-25 | 1990-06-19 | Peter J. Balsells | Coiled spring electromagnetic shielding gasket |
EP0339544B1 (en) | 1988-04-25 | 1993-09-22 | Peter J. Balsells | Garter spring with canted back angle located on outside diameter |
US5117066A (en) | 1988-04-25 | 1992-05-26 | Peter J. Balsells | Retaining and locking electromagnetic gasket |
US4826144A (en) | 1988-04-25 | 1989-05-02 | Peter J. Balsells | Inside back angle canted coil spring |
US5203849A (en) | 1990-03-20 | 1993-04-20 | Balsells Peter J | Canted coil spring in length filled with an elastomer |
US4830344A (en) | 1988-04-25 | 1989-05-16 | Peter J. Balsells | Canted-coil spring with turn angle and seal |
US5006346A (en) | 1988-04-28 | 1991-04-09 | Alza Corporation | Delivery system |
US5024842A (en) | 1988-04-28 | 1991-06-18 | Alza Corporation | Annealed coats |
US5160743A (en) | 1988-04-28 | 1992-11-03 | Alza Corporation | Annealed composition for pharmaceutically acceptable drug |
US4931285A (en) | 1988-04-28 | 1990-06-05 | Alza Corporation | Aqueous based pharmaceutical coating composition for dosage forms |
JP2794022B2 (en) | 1988-11-11 | 1998-09-03 | 三生製薬株式会社 | Transdermal preparation containing bunazosin or its salts |
US5728088A (en) | 1988-12-13 | 1998-03-17 | Alza Corporation | Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals |
US5057318A (en) | 1988-12-13 | 1991-10-15 | Alza Corporation | Delivery system for beneficial agent over a broad range of rates |
US5059423A (en) | 1988-12-13 | 1991-10-22 | Alza Corporation | Delivery system comprising biocompatible beneficial agent formulation |
US5110596A (en) | 1988-12-13 | 1992-05-05 | Alza Corporation | Delivery system comprising means for delivering agent to livestock |
US5034229A (en) | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
US5234424A (en) | 1988-12-28 | 1993-08-10 | Alza Corporation | Osmotically driven syringe |
US4969884A (en) | 1988-12-28 | 1990-11-13 | Alza Corporation | Osmotically driven syringe |
US4976966A (en) | 1988-12-29 | 1990-12-11 | Alza Corporation | Delayed release osmotically driven fluid dispenser |
US5288479A (en) | 1989-01-17 | 1994-02-22 | Sterling Drug, Inc. | Extrudable elastic oral pharmaceutical gel compositions and metered dose dispensers containing them and method of making and method of use thereof |
US5705363A (en) | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
US5906816A (en) | 1995-03-16 | 1999-05-25 | University Of Florida | Method for treatment of autoimmune diseases |
US5219572A (en) | 1989-03-17 | 1993-06-15 | Pitman-Moore, Inc. | Controlled release delivery device for macromolecular proteins |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5126142A (en) | 1989-07-18 | 1992-06-30 | Alza Corporation | Dispenser comprising ionophore |
US5112614A (en) | 1989-09-14 | 1992-05-12 | Alza Corporation | Implantable delivery dispenser |
US5290558A (en) | 1989-09-21 | 1994-03-01 | Osteotech, Inc. | Flowable demineralized bone powder composition and its use in bone repair |
SE465950B (en) | 1989-10-23 | 1991-11-25 | Medinvent Sa | Combination of an aggregate particle size, crystalline or freeze-dried drug with a pseudoplastic gel for preparation of an injectable preparation as well as a process for its preparation |
DE69003805T2 (en) | 1989-11-13 | 1994-05-19 | Becton Dickinson France | STORAGE CONTAINER FOR A COMPONENT OF A MEDICINAL SOLUTION. |
JPH03236317A (en) | 1989-12-06 | 1991-10-22 | Sansei Seiyaku Kk | Dopamine derivative-containing percutaneous |
US5030216A (en) | 1989-12-15 | 1991-07-09 | Alza Corporation | Osmotically driven syringe |
US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5213809A (en) | 1990-01-24 | 1993-05-25 | Alza Corporation | Delivery system comprising means for controlling internal pressure |
US5223266A (en) | 1990-01-24 | 1993-06-29 | Alza Corporation | Long-term delivery device with early startup |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US5122128A (en) | 1990-03-15 | 1992-06-16 | Alza Corporation | Orifice insert for a ruminal bolus |
US5120306A (en) | 1990-03-21 | 1992-06-09 | Gosselin Leon F | Direct delivery of anti-inflammatories to the proximal small bowel |
US5207752A (en) | 1990-03-30 | 1993-05-04 | Alza Corporation | Iontophoretic drug delivery system with two-stage delivery profile |
US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
US5091188A (en) | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
US5290271A (en) | 1990-05-14 | 1994-03-01 | Jernberg Gary R | Surgical implant and method for controlled release of chemotherapeutic agents |
US5374620A (en) | 1990-06-07 | 1994-12-20 | Genentech, Inc. | Growth-promoting composition and its use |
US5180591A (en) | 1990-07-11 | 1993-01-19 | Alza Corporation | Delivery device with a protective sleeve |
US5234693A (en) | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
US5234692A (en) | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
US5234695A (en) | 1990-07-24 | 1993-08-10 | Eastman Kodak Company | Water dispersible vitamin E composition |
US5300302A (en) | 1990-10-04 | 1994-04-05 | Nestec S.A. | Pharmaceutical composition in gel form in a dispensing package |
US5529914A (en) | 1990-10-15 | 1996-06-25 | The Board Of Regents The Univeristy Of Texas System | Gels for encapsulation of biological materials |
US5151093A (en) | 1990-10-29 | 1992-09-29 | Alza Corporation | Osmotically driven syringe with programmable agent delivery |
IT1243390B (en) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION. |
US5161806A (en) | 1990-12-17 | 1992-11-10 | Peter J. Balsells | Spring-loaded, hollow, elliptical ring seal |
GB9027422D0 (en) | 1990-12-18 | 1991-02-06 | Scras | Osmotically driven infusion device |
MX9200038A (en) | 1991-01-09 | 1992-11-01 | Alza Corp | BIODEGRADABLE DEVICES AND COMPOSITIONS FOR THE RELEASE BY DIFFUSION OF AGENTS. |
US5443459A (en) | 1991-01-30 | 1995-08-22 | Alza Corporation | Osmotic device for delayed delivery of agent |
US5861166A (en) | 1991-03-12 | 1999-01-19 | Alza Corporation | Delivery device providing beneficial agent stability |
US5113938A (en) | 1991-05-07 | 1992-05-19 | Clayton Charley H | Whipstock |
US5137727A (en) | 1991-06-12 | 1992-08-11 | Alza Corporation | Delivery device providing beneficial agent stability |
EP0520119A1 (en) | 1991-06-17 | 1992-12-30 | Spirig Ag Pharmazeutische Präparate | New oral diclofenac composition |
US5252338A (en) | 1991-06-27 | 1993-10-12 | Alza Corporation | Therapy delayed |
US5190765A (en) | 1991-06-27 | 1993-03-02 | Alza Corporation | Therapy delayed |
US5288214A (en) | 1991-09-30 | 1994-02-22 | Toshio Fukuda | Micropump |
YU87892A (en) | 1991-10-01 | 1995-12-04 | Eli Lilly And Company Lilly Corporate Center | INJECTIBLE LONG TERM RELEASE FORMULATIONS AND PROCEDURES FOR THEIR OBTAINING AND USE |
EP0607321A1 (en) | 1991-10-10 | 1994-07-27 | Alza Corporation | Osmotic drug delivery devices with hydrophobic wall materials |
US5318780A (en) | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
US5236707A (en) | 1991-11-08 | 1993-08-17 | Dallas Biotherapeutics, Inc. | Stabilization of human interferon |
AU3136293A (en) | 1991-11-15 | 1993-06-15 | Isp Investments Inc. | Pharmaceutical tablet with pvp having an enhanced drug dissolution rate |
DE4137649C2 (en) | 1991-11-15 | 1997-11-20 | Gerhard Dingler | Component |
US5200195A (en) | 1991-12-06 | 1993-04-06 | Alza Corporation | Process for improving dosage form delivery kinetics |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5223265A (en) | 1992-01-10 | 1993-06-29 | Alza Corporation | Osmotic device with delayed activation of drug delivery |
US5676942A (en) | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
US5209746A (en) | 1992-02-18 | 1993-05-11 | Alza Corporation | Osmotically driven delivery devices with pulsatile effect |
US5456679A (en) | 1992-02-18 | 1995-10-10 | Alza Corporation | Delivery devices with pulsatile effect |
US5308348A (en) | 1992-02-18 | 1994-05-03 | Alza Corporation | Delivery devices with pulsatile effect |
US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5221278A (en) | 1992-03-12 | 1993-06-22 | Alza Corporation | Osmotically driven delivery device with expandable orifice for pulsatile delivery effect |
WO1993019739A1 (en) | 1992-03-30 | 1993-10-14 | Alza Corporation | Viscous suspensions of controlled-release drug particles |
AU3941793A (en) | 1992-03-30 | 1993-11-08 | Alza Corporation | Additives for bioerodible polymers to regulate degradation |
US6197346B1 (en) | 1992-04-24 | 2001-03-06 | Brown Universtiy Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
FR2690622B1 (en) | 1992-04-29 | 1995-01-20 | Chronotec | Programmable ambulatory infusion pump system. |
US5314685A (en) | 1992-05-11 | 1994-05-24 | Agouron Pharmaceuticals, Inc. | Anhydrous formulations for administering lipophilic agents |
US5711968A (en) | 1994-07-25 | 1998-01-27 | Alkermes Controlled Therapeutics, Inc. | Composition and method for the controlled release of metal cation-stabilized interferon |
US5413672A (en) | 1992-07-22 | 1995-05-09 | Ngk Insulators, Ltd. | Method of etching sendust and method of pattern-etching sendust and chromium films |
US5512293A (en) | 1992-07-23 | 1996-04-30 | Alza Corporation | Oral sustained release drug delivery device |
US5609885A (en) | 1992-09-15 | 1997-03-11 | Alza Corporation | Osmotic membrane and delivery device |
GB9223146D0 (en) | 1992-11-05 | 1992-12-16 | Scherer Corp R P | Vented capsule |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
SE9203594D0 (en) | 1992-11-30 | 1992-11-30 | Christer Nystroem | DISPERSA SYSTEM MEDICINAL PRODUCT |
US5368588A (en) | 1993-02-26 | 1994-11-29 | Bettinger; David S. | Parenteral fluid medication reservoir pump |
WO1994021262A1 (en) | 1993-03-17 | 1994-09-29 | Alza Corporation | Device for the transdermal administration of alprazolam |
US5514110A (en) | 1993-03-22 | 1996-05-07 | Teh; Eutiquio L. | Automatic flow control device |
US6284727B1 (en) | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
NZ250844A (en) | 1993-04-07 | 1996-03-26 | Pfizer | Treatment of non-insulin dependant diabetes with peptides; composition |
NZ247516A (en) | 1993-04-28 | 1995-02-24 | Bernard Charles Sherman | Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5639477A (en) | 1993-06-23 | 1997-06-17 | Alza Corporation | Ruminal drug delivery device |
JPH08512054A (en) | 1993-06-25 | 1996-12-17 | アルザ・コーポレーション | Inclusion of poly-N-vinylamide in transdermal system |
US5498255A (en) | 1993-08-17 | 1996-03-12 | Alza Corporation | Osmotic device for protracted pulsatile delivery of agent |
JP2700141B2 (en) | 1993-09-17 | 1998-01-19 | 富士化学工業株式会社 | Calcium hydrogen phosphate, its production method and excipient using the same |
NZ275615A (en) | 1993-09-29 | 1996-11-26 | Alza Corp | Oxybutynin composition containing monoglyceride and lactate ester as permeability enhancers; device for transdermal administration of oxybutynin |
US5540665A (en) | 1994-01-31 | 1996-07-30 | Alza Corporation | Gas driven dispensing device and gas generating engine therefor |
AU691249B2 (en) | 1994-02-04 | 1998-05-14 | Lipocore Holding Ab | Bilayer preparations |
US5697975A (en) | 1994-02-09 | 1997-12-16 | The University Of Iowa Research Foundation | Human cerebral cortex neural prosthetic for tinnitus |
US5458888A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
EP0741577B1 (en) | 1994-03-07 | 2002-11-06 | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE | The use of interferon subtype alpha 8 in the preparation of medicaments to treat viral infections of the liver |
ZA953078B (en) | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
WO1995034285A1 (en) | 1994-06-13 | 1995-12-21 | Alza Corporation | Dosage form for administering drug in liquid formulation |
NL9401150A (en) | 1994-07-12 | 1996-02-01 | Nederland Ptt | Method for presenting on a receiving side a first number of video signals originating from a transmitting side, as well as a system, as well as a transmitter, as well as a network, and also a receiver. |
ES2153485T3 (en) | 1994-07-13 | 2001-03-01 | Alza Corp | COMPOSITION AND PROCEDURE THAT INCREASES THE PERCUTANEOUS DIFFUSION BY ELECTROTRANSPORT OF A SUBSTANCE. |
US5633011A (en) | 1994-08-04 | 1997-05-27 | Alza Corporation | Progesterone replacement therapy |
US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5595759A (en) | 1994-11-10 | 1997-01-21 | Alza Corporation | Process for providing therapeutic composition |
DK0788351T3 (en) | 1994-11-10 | 2003-05-26 | Univ Kentucky Res Found | Implantable, refillable device for speed-controlled drug delivery directly to an internal part of the body |
FR2731150B1 (en) | 1995-03-03 | 1997-04-18 | Oreal | USE OF AMPHIPHILIC COMPOUNDS AS A THICKENING AGENT FOR NON-AQUEOUS MEDIA |
US5595751A (en) | 1995-03-06 | 1997-01-21 | Ethicon, Inc. | Absorbable polyoxaesters containing amines and/or amido groups |
US5648088A (en) | 1995-03-06 | 1997-07-15 | Ethicon, Inc. | Blends of absorbable polyoxaesters containing amines and/or amide groups |
US6100346A (en) | 1995-03-06 | 2000-08-08 | Ethicon, Inc. | Copolymers of polyoxaamides |
US5859150A (en) | 1995-03-06 | 1999-01-12 | Ethicon, Inc. | Prepolymers of absorbable polyoxaesters |
US5464929A (en) | 1995-03-06 | 1995-11-07 | Ethicon, Inc. | Absorbable polyoxaesters |
US6147168A (en) | 1995-03-06 | 2000-11-14 | Ethicon, Inc. | Copolymers of absorbable polyoxaesters |
US5962023A (en) | 1995-03-06 | 1999-10-05 | Ethicon, Inc. | Hydrogels containing absorbable polyoxaamides |
US5607687A (en) | 1995-03-06 | 1997-03-04 | Ethicon, Inc. | Polymer blends containing absorbable polyoxaesters |
US5700583A (en) | 1995-03-06 | 1997-12-23 | Ethicon, Inc. | Hydrogels of absorbable polyoxaesters containing amines or amido groups |
US6403655B1 (en) | 1995-03-06 | 2002-06-11 | Ethicon, Inc. | Method of preventing adhesions with absorbable polyoxaesters |
US5618552A (en) | 1995-03-06 | 1997-04-08 | Ethicon, Inc. | Absorbable polyoxaesters |
US5698213A (en) | 1995-03-06 | 1997-12-16 | Ethicon, Inc. | Hydrogels of absorbable polyoxaesters |
US5844017A (en) | 1995-03-06 | 1998-12-01 | Ethicon, Inc. | Prepolymers of absorbable polyoxaesters containing amines and/or amido groups |
US5597579A (en) | 1995-03-06 | 1997-01-28 | Ethicon, Inc. | Blends of absorbable polyoxaamides |
US5736159A (en) | 1995-04-28 | 1998-04-07 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water insoluble drugs in which a passageway is formed in situ |
CN1170596C (en) | 1995-05-02 | 2004-10-13 | 大正制药株式会社 | Composition for oral administration |
US5939286A (en) | 1995-05-10 | 1999-08-17 | University Of Florida | Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them |
US5882676A (en) | 1995-05-26 | 1999-03-16 | Alza Corporation | Skin permeation enhancer compositions using acyl lactylates |
WO1996039142A1 (en) | 1995-06-06 | 1996-12-12 | F. Hoffmann-La Roche Ag | Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride |
US5904935A (en) | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
US5690952A (en) | 1995-06-07 | 1997-11-25 | Judy A. Magruder et al. | Implantable system for delivery of fluid-sensitive agents to animals |
IL122432A (en) | 1995-06-07 | 2000-07-16 | Cygnus Therapeutic Systems | Transdermal patch for preventing ovulation |
US7833543B2 (en) | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
US6572879B1 (en) | 1995-06-07 | 2003-06-03 | Alza Corporation | Formulations for transdermal delivery of pergolide |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
US6129761A (en) | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
US5782396A (en) | 1995-08-28 | 1998-07-21 | United States Surgical Corporation | Surgical stapler |
US5906830A (en) | 1995-09-08 | 1999-05-25 | Cygnus, Inc. | Supersaturated transdermal drug delivery systems, and methods for manufacturing the same |
GB9521125D0 (en) | 1995-10-16 | 1995-12-20 | Unilever Plc | Cosmetic composition |
US5766620A (en) | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
GB9521805D0 (en) | 1995-10-25 | 1996-01-03 | Cortecs Ltd | Solubilisation methods |
PT771817E (en) | 1995-10-30 | 2003-06-30 | Oleoyl Estrone Developments S | OLEATE ESTERS OF ESTROGEN FOR THE TREATMENT OF OBESITY AND / OR EXCESS OF WEIGHT |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
AUPN723395A0 (en) | 1995-12-19 | 1996-01-18 | Macnaught Medical Pty Limited | Lubrication methods |
US6395292B2 (en) | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
US6132420A (en) | 1996-02-02 | 2000-10-17 | Alza Corporation | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
US6156331A (en) | 1996-02-02 | 2000-12-05 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
AU2526497A (en) | 1996-02-02 | 1997-08-22 | Rhomed Incorporated | Post-labeling stabilization of radiolabeled proteins and peptides |
US6261584B1 (en) | 1996-02-02 | 2001-07-17 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
SK284136B6 (en) | 1996-02-02 | 2004-09-08 | Alza Corporation | Implantable device for delivering leuprolide to a fluid medium |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
NZ330973A (en) | 1996-03-08 | 2000-03-27 | Zeneca Ltd | Azolobenzazepine derivatives as neurologically active agents |
JP2000506865A (en) | 1996-03-14 | 2000-06-06 | ジ イミューン リスポンス コーポレイション | Targeted delivery of genes encoding interferons |
US5703200A (en) | 1996-03-15 | 1997-12-30 | Ethicon, Inc. | Absorbable copolymers and blends of 6,6-dialkyl-1,4-dioxepan-2-one and its cyclic dimer |
US5660858A (en) | 1996-04-03 | 1997-08-26 | Research Triangle Pharmaceuticals | Cyclosporin emulsions |
US6204022B1 (en) | 1996-04-12 | 2001-03-20 | Pepgen Corporation And University Of Florida | Low-toxicity human interferon-alpha analogs |
US6074673A (en) | 1996-04-22 | 2000-06-13 | Guillen; Manuel | Slow-release, self-absorbing, drug delivery system |
US5976109A (en) | 1996-04-30 | 1999-11-02 | Medtronic, Inc. | Apparatus for drug infusion implanted within a living body |
EP0928136B1 (en) | 1996-06-05 | 2003-10-22 | Ashmont Holdings Limited | Injectable compositions |
US6767887B1 (en) | 1996-06-05 | 2004-07-27 | Roche Diagnostics Gmbh | Exendin analogues, processes for their preparation and medicaments containing them |
DE29610419U1 (en) | 1996-06-14 | 1996-10-24 | Filtertek, S.A., Plailly | Gravity infusion device for medical infusions |
GB9613858D0 (en) | 1996-07-02 | 1996-09-04 | Cortecs Ltd | Hydrophobic preparations |
EP0909175B1 (en) | 1996-07-03 | 2003-06-04 | Alza Corporation | Non-aqueous protic peptide formulations |
US5916582A (en) | 1996-07-03 | 1999-06-29 | Alza Corporation | Aqueous formulations of peptides |
US5932547A (en) | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
ATE322272T1 (en) | 1996-07-15 | 2006-04-15 | Alza Corp | NEW FORMULATIONS FOR TRANSDERMAL ADMINISTRATION OF FLUOXETINE |
AR008789A1 (en) | 1996-07-31 | 2000-02-23 | Bayer Corp | PIRIDINES AND SUBSTITUTED BIPHENYLS |
DK0966297T4 (en) | 1996-08-08 | 2013-03-18 | Amylin Pharmaceuticals Llc | Regulation of gastrointestinal motility |
US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
IN184589B (en) | 1996-10-16 | 2000-09-09 | Alza Corp | |
ES2191834T3 (en) | 1996-10-24 | 2003-09-16 | Alza Corp | AGENTS THAT FACILITATE THE PERMEATION AND DESTINATIONS FOR COMPOSITIONS, DEVICES AND PROCEDURES OF TRANSDERMAL CONTRIBUTION OF DRUGS. |
US5817129A (en) | 1996-10-31 | 1998-10-06 | Ethicon, Inc. | Process and apparatus for coating surgical sutures |
UA65549C2 (en) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight |
DE19646392A1 (en) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery |
US5928666A (en) | 1996-11-12 | 1999-07-27 | Cygnus Inc. | Crystalline form of estradiol and pharmaceutical formulations comprising same |
DK1066081T3 (en) | 1996-11-15 | 2003-12-01 | Alza Corp | Osmotic delivery system and method to improve the commissioning and implementation of osmotic delivery systems |
CA2591581C (en) | 1996-12-20 | 2013-01-29 | Alza Corporation | Gel composition and methods |
GB9626513D0 (en) | 1996-12-20 | 1997-02-05 | Bioglan Ireland R & D Ltd | A pharmaceutical composition |
ATE304864T1 (en) | 1997-01-07 | 2005-10-15 | Amylin Pharmaceuticals Inc | USE OF EXEDINES AND THEIR ANTAGONISTS TO REDUCE FOOD INTAKE |
JP2001511128A (en) | 1997-01-28 | 2001-08-07 | ファルマシア・アンド・アップジョン・カンパニー | Lyophilized product of lipid complex of water-insoluble porphyrin |
ZA981610B (en) | 1997-03-24 | 1999-08-26 | Alza Corp | Self adjustable exit port. |
US5874388A (en) | 1997-04-02 | 1999-02-23 | Dow Corning Corporation | Lubricant composition for disc brake caliper pin and a disc brake asembly containing the lubricant |
US6127520A (en) | 1997-04-15 | 2000-10-03 | Regents Of The University Of Michigan | Compositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles |
EP0975331A1 (en) | 1997-04-17 | 2000-02-02 | Dumex-Alpharma A/S | A novel bioadhesive drug delivery system based on liquid crystals |
CA2288306A1 (en) * | 1997-04-28 | 1998-11-05 | Rhone-Poulenc Rorer S.A. | Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors |
US20020039594A1 (en) | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
US6663899B2 (en) | 1997-06-13 | 2003-12-16 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
SI9700186B (en) | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Novel pharmaceutical preparation with controlled release of active healing substances |
MY125849A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
US6172046B1 (en) | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
PL195212B1 (en) | 1997-09-29 | 2007-08-31 | Nektar Therapeutics | Perforated microparticles and method of using them |
JPH11100353A (en) | 1997-09-29 | 1999-04-13 | Esupo Kk | Refined and deodorized liquid ester wax and its composition |
US6133429A (en) | 1997-10-03 | 2000-10-17 | Becton Dickinson And Company | Chromophores useful for the preparation of novel tandem conjugates |
ES2297902T5 (en) | 1997-11-14 | 2013-07-09 | Amylin Pharmaceuticals, Inc. | Novel agonist compounds from exendina |
US6299869B1 (en) | 1997-12-08 | 2001-10-09 | Genentech, Inc. | Human interferon-epsilon: a type I interferon |
US6368612B1 (en) | 1997-12-12 | 2002-04-09 | Biohybrid Technologies Llc | Devices for cloaking transplanted cells |
JP4215188B2 (en) | 1997-12-22 | 2009-01-28 | インターシア セラピューティクス,インコーポレイティド | Rate-regulating membranes for devices that regulate drug delivery |
CA2316976C (en) | 1997-12-29 | 2009-02-17 | Alza Corporation | Osmotic delivery system with membrane plug retention mechanism |
JP4188560B2 (en) | 1997-12-29 | 2008-11-26 | インターシア セラピューティクス,インコーポレイティド | Transplant device for subcutaneous implant |
DE69836149T2 (en) | 1997-12-30 | 2007-08-16 | Alza Corp., Mountain View | ADMINISTRATIVE SYSTEM FOR ACTIVE SUBSTANCES USING A MEMBRANE PAD |
US20040024068A1 (en) | 1998-01-23 | 2004-02-05 | Trustees Of Tufts College | Antimicrobial compounds |
IT1298575B1 (en) | 1998-02-06 | 2000-01-12 | Vectorpharma Int | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF NANOPARTICLES INCLUDING LIPID SUBSTANCES AND ANTIPHILIC SUBSTANCES AND RELATED PROCESS OF |
US6017545A (en) | 1998-02-10 | 2000-01-25 | Modi; Pankaj | Mixed micellar delivery system and method of preparation |
AU759058C (en) | 1998-02-13 | 2005-09-15 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
US6703359B1 (en) | 1998-02-13 | 2004-03-09 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
US6224577B1 (en) | 1998-03-02 | 2001-05-01 | Medrad, Inc. | Syringes and plungers for use therein |
US6245357B1 (en) | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
US6183461B1 (en) | 1998-03-11 | 2001-02-06 | Situs Corporation | Method for delivering a medication |
EP0984039A4 (en) | 1998-03-12 | 2002-01-02 | Daicel Chem | Lactone-containing resin composition, molded object thereof, and film |
US6029361A (en) | 1998-03-25 | 2000-02-29 | Ultratech Stepper, Inc. | Air-guage nozzle probe structure for microlithographic image focusing |
US6074660A (en) | 1998-04-20 | 2000-06-13 | Ethicon, Inc. | Absorbable polyoxaesters containing amines and/ or amido groups |
TW586944B (en) | 1998-05-29 | 2004-05-11 | Sumitomo Pharma | Controlled release agent having a multi-layer structure |
CA2334872C (en) | 1998-06-12 | 2014-08-19 | Bionebraska, Inc. | Use of exendin-4 to treat impaired glucose tolerance |
US7390637B2 (en) | 1998-07-21 | 2008-06-24 | Human Genome Sciences, Inc. | Keratinocyte derived interferon |
US6472512B1 (en) | 1998-07-21 | 2002-10-29 | Human Genome Sciences, Inc. | Keratinocyte derived interferon |
US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
US6551613B1 (en) | 1998-09-08 | 2003-04-22 | Alza Corporation | Dosage form comprising therapeutic formulation |
US6174547B1 (en) | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
EP1112060B1 (en) | 1998-09-09 | 2005-12-07 | ALZA Corporation | Dosage form comprising liquid formulation |
US6248112B1 (en) | 1998-09-30 | 2001-06-19 | C. R. Bard, Inc. | Implant delivery system |
US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
EP1126827A2 (en) | 1998-11-02 | 2001-08-29 | Alza Corporation | Controlled delivery of active agents |
WO2000029206A1 (en) | 1998-11-13 | 2000-05-25 | Sensor Technologies Inc. | Monodisperse preparations useful with implanted devices |
US20030060425A1 (en) | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
BR9915961A (en) | 1998-12-07 | 2001-08-21 | Sod Conseils Rech Applic | Glp-1 analogs |
WO2000035419A2 (en) | 1998-12-17 | 2000-06-22 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
CN1158068C (en) | 1998-12-23 | 2004-07-21 | 安姆根有限公司 | Polyol/oil suspensions for the sustained release of proteins |
EP1140144A4 (en) | 1998-12-31 | 2002-10-30 | Viragen Inc | Composition of highly purified natural mixtures of type i interferon derived from leukocytes and methods |
ES2196918T3 (en) | 1998-12-31 | 2003-12-16 | Alza Corp | OSMOTIC SUPPLY SYSTEM EQUIPPED WITH PISTON WITH SPACE ECONOMY. |
US6433144B1 (en) | 1999-01-12 | 2002-08-13 | Viragen, Inc. | Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods |
WO2000040273A2 (en) | 1999-01-08 | 2000-07-13 | Vical Incorporated | Treatment of viral diseases using an interferon omega expressing polynucleotide |
US6703225B1 (en) | 1999-01-12 | 2004-03-09 | Sumitomo Pharmaceuticals Company, Limited | Interferon-α |
NZ512657A (en) | 1999-01-14 | 2004-01-30 | Amylin Pharmaceuticals Inc | Glucagon suppression |
US7399489B2 (en) | 1999-01-14 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Exendin analog formulations |
ES2244416T5 (en) | 1999-01-14 | 2020-01-03 | Amylin Pharmaceuticals Llc | Novel formulations of exendon agonists and their administration methods |
US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
US7919109B2 (en) | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
KR100858856B1 (en) | 1999-02-08 | 2008-09-17 | 인타르시아 세라퓨틱스 인코포레이티드 | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
US6451974B1 (en) | 1999-03-17 | 2002-09-17 | Novo Nordisk A/S | Method of acylating peptides and novel acylating agents |
US6835194B2 (en) | 1999-03-18 | 2004-12-28 | Durect Corporation | Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners |
US6541021B1 (en) | 1999-03-18 | 2003-04-01 | Durect Corporation | Devices and methods for pain management |
GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
BR0009840A (en) | 1999-04-19 | 2002-01-08 | Schering Corp | Combination therapy for hcv, containing ribavirin in combination with antioxidants |
US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
DK1180121T3 (en) | 1999-05-17 | 2004-03-01 | Conjuchem Inc | Long-acting insulinotropic peptides |
US6514500B1 (en) | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US6506724B1 (en) | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
JP2003501404A (en) | 1999-06-04 | 2003-01-14 | デルルックス ファーマシューティカル コーポレイション | Preparation comprising dehydrated particles of drug and method of preparing same |
US20030059376A1 (en) | 1999-06-04 | 2003-03-27 | Libbey Miles A. | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
NZ530701A (en) | 1999-06-04 | 2005-09-30 | Alza Corp | Implantable gel compositions comprising compressed particles including the active agent in a bioerodible gel |
US6833256B1 (en) | 1999-06-22 | 2004-12-21 | University Of Maryland | Interferon tau mutants and methods for making them |
US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
US6436091B1 (en) | 1999-11-16 | 2002-08-20 | Microsolutions, Inc. | Methods and implantable devices and systems for long term delivery of a pharmaceutical agent |
US7022674B2 (en) | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
AU2092701A (en) | 1999-12-17 | 2001-06-25 | Durect Corporation | Devices and methods in intracerebrospinal delivery of morphine-6-glucuronide |
WO2001045675A2 (en) | 1999-12-21 | 2001-06-28 | Alza Corporation | Valve for osmotic devices |
US6283949B1 (en) | 1999-12-27 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Refillable implantable drug delivery pump |
US6572890B2 (en) | 2000-01-13 | 2003-06-03 | Osmotica Corp. | Osmotic device containing venlafaxine and an anti-psychotic agent |
US6472060B1 (en) | 2000-01-19 | 2002-10-29 | Seco Tools Ab | Coated body with nanocrystalline CVD coating for enhanced edge toughness and reduced friction |
US6844321B2 (en) | 2000-01-31 | 2005-01-18 | Novo Nordisk A/S | Crystallization of a GLP-1 analogue |
US6465425B1 (en) | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
US6471688B1 (en) | 2000-02-15 | 2002-10-29 | Microsolutions, Inc. | Osmotic pump drug delivery systems and methods |
US6464688B1 (en) | 2000-02-15 | 2002-10-15 | Microsolutions, Inc. | Osmotic pump delivery system with flexible drug compartment |
WO2001068112A2 (en) | 2000-03-14 | 2001-09-20 | Goeke Burkhard | Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility |
US20030211974A1 (en) | 2000-03-21 | 2003-11-13 | Brodbeck Kevin J. | Gel composition and methods |
AU2001259111B2 (en) | 2000-04-19 | 2005-12-08 | Durect Corporation | Sustained release formulations comprising growth hormone |
CA2407074A1 (en) | 2000-04-21 | 2001-11-01 | Jukka Hartikka | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
JP2001357075A (en) | 2000-04-27 | 2001-12-26 | El-Con System Co Ltd | System and method for calculating quantity of materials while utilizing two-dimensional cad interface |
DE60134403D1 (en) | 2000-05-19 | 2008-07-24 | Amylin Pharmaceuticals Inc | TREATMENT OF ACUTE CORONARY SYNDROME WITH GLP-1 |
US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
BR0111562A (en) | 2000-06-16 | 2003-04-15 | Lilly Co Eli | Glucagon-like peptide 1 analogs |
US6479065B2 (en) | 2000-08-10 | 2002-11-12 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
US6824822B2 (en) | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
CA2423431A1 (en) | 2000-10-06 | 2002-04-11 | Durect Corporation | Devices and methods for management of inflammation |
CA2427194A1 (en) | 2000-11-03 | 2002-05-10 | Biomedicines, Inc. | Method for short-term and long-term drug dosimetry |
EP1335704A2 (en) | 2000-11-16 | 2003-08-20 | Durect Corporation | Implant dosage form and use thereof for the delivery of a cholesterol lowering agent |
JP4248236B2 (en) | 2000-11-29 | 2009-04-02 | デュレクト コーポレイション | Device and method for controlling delivery from a drug delivery device |
US20020165286A1 (en) | 2000-12-08 | 2002-11-07 | Hanne Hedeman | Dermal anti-inflammatory composition |
EP1351984A2 (en) | 2000-12-13 | 2003-10-15 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
CA2431173A1 (en) | 2000-12-13 | 2002-06-20 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
JP2004515533A (en) | 2000-12-14 | 2004-05-27 | アミリン・ファーマシューティカルズ,インコーポレイテッド | Peptide YY and peptide YY agonist for treating metabolic disorders |
IN188924B (en) | 2001-03-01 | 2002-11-23 | Bharat Serums & Vaccines Ltd | |
CA2440387A1 (en) | 2001-03-23 | 2002-10-03 | Durect Corporation | Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space |
US6632217B2 (en) | 2001-04-19 | 2003-10-14 | Microsolutions, Inc. | Implantable osmotic pump |
JP2005506956A (en) | 2001-06-01 | 2005-03-10 | イーライ・リリー・アンド・カンパニー | Long-acting GLP-1 formulation |
US6514517B2 (en) | 2001-06-20 | 2003-02-04 | Ethicon, Inc. | Antimicrobial coatings for medical devices |
US7318931B2 (en) | 2001-06-21 | 2008-01-15 | Genentech, Inc. | Sustained release formulation |
EP1401503B1 (en) | 2001-06-22 | 2007-05-09 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer |
US7163688B2 (en) | 2001-06-22 | 2007-01-16 | Alza Corporation | Osmotic implant with membrane and membrane retention means |
US20030138403A1 (en) | 2001-06-29 | 2003-07-24 | Maxygen Aps | Interferon formulations |
AU2002317599B2 (en) | 2001-07-31 | 2008-04-03 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GLP-1 exendin-4 peptide analogs and uses thereof |
EP1432730A4 (en) | 2001-08-23 | 2006-10-11 | Lilly Co Eli | Glucagon-like peptide-1 analogs |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
WO2003024357A2 (en) | 2001-09-14 | 2003-03-27 | Martin Francis J | Microfabricated nanopore device for sustained release of therapeutic agent |
ATE443513T1 (en) | 2001-09-17 | 2009-10-15 | Durect Corp | DEVICE AND METHOD FOR ACCURATE DELIVERY OF AN ACTIVE SUBSTANCE |
AU2002332054B2 (en) | 2001-09-24 | 2007-11-08 | Imperial Innovations Limited | Modification of feeding behavior |
US7041646B2 (en) | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
CA2460690A1 (en) | 2001-10-05 | 2003-04-17 | Intermune, Inc. | Method of treating hepatitis virus infection with a multiphasic interferon delivery profile |
WO2003063573A2 (en) | 2001-11-09 | 2003-08-07 | Intarcia Therapeutics, Inc. | Method for treating diseases with omega interferon |
DE60232987D1 (en) | 2001-11-14 | 2009-08-27 | Durect Corp | INJECTABLE DEPOT COMPOSITIONS |
EP1446100B1 (en) | 2001-11-14 | 2011-05-04 | Durect Corporation | Injectable depot compositions and uses thereof |
JP2005519873A (en) | 2001-11-14 | 2005-07-07 | アルザ・コーポレーション | Catheter injectable depot compositions and their use |
US20030108608A1 (en) | 2001-12-12 | 2003-06-12 | Erik Laridon | Thermoplastic articles comprising silver-containing antimicrobials and high amounts of carboxylic acid salts for increased surface-available silver |
CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
US7105489B2 (en) | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
GB2386066A (en) | 2002-02-28 | 2003-09-10 | Norbrook Lab Ltd | Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species |
GB0204722D0 (en) | 2002-02-28 | 2002-04-17 | Norferm Da | Method |
EP1572915A4 (en) | 2002-04-11 | 2011-01-05 | Medimmune Vaccines Inc | Preservation of bioactive materials by spray drying |
KR20050026402A (en) | 2002-06-17 | 2005-03-15 | 알자 코포레이션 | Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
ATE376854T1 (en) | 2002-06-26 | 2007-11-15 | Alza Corp | MINIMALLY FORGIVE VOLUME EFFICIENT PISTON FOR OSMOTIC DRUG DELIVERY SYSTEMS |
US7177526B2 (en) | 2002-06-28 | 2007-02-13 | Intel Corporation | System and method for improving audio during post-production of video recordings |
IL166418A0 (en) | 2002-07-31 | 2006-01-15 | Alza Corp | Injectable depot compositions and uses thereof |
US8501215B2 (en) | 2002-07-31 | 2013-08-06 | Guohua Chen | Injectable multimodal polymer depot compositions and uses thereof |
US20080260838A1 (en) | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
JP2006506386A (en) | 2002-10-22 | 2006-02-23 | ワラタ ファーマシューティカルズ, インコーポレイテッド | Diabetes treatment |
BR0315304A (en) | 2002-11-06 | 2005-08-16 | Alza Corp | Depot formulations for controlled release |
US6969702B2 (en) | 2002-11-20 | 2005-11-29 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
US7014636B2 (en) * | 2002-11-21 | 2006-03-21 | Alza Corporation | Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel |
US7790681B2 (en) | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US20040224903A1 (en) | 2002-12-19 | 2004-11-11 | Stephen Berry | Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device |
GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
JP2004238392A (en) | 2003-01-14 | 2004-08-26 | Nipro Corp | Stabilized proteinic preparation |
CA2520610A1 (en) | 2003-03-31 | 2004-10-21 | Alza Corporation | Osmotic pump with means for dissipating internal pressure |
TW200509999A (en) | 2003-03-31 | 2005-03-16 | Alza Corp | Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems |
US20050008661A1 (en) | 2003-03-31 | 2005-01-13 | Fereira Pamela J. | Non-aqueous single phase vehicles and formulations utilizing such vehicles |
EP1982772A1 (en) | 2003-05-16 | 2008-10-22 | Cinvention Ag | Bio-compatible coated medical implants |
US20050079202A1 (en) | 2003-05-30 | 2005-04-14 | Guohua Chen | Implantable elastomeric depot compositions and uses thereof |
WO2005000222A2 (en) | 2003-05-30 | 2005-01-06 | Amylin Pharmaceuticals, Inc. | Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins |
ATE541582T1 (en) | 2003-06-03 | 2012-02-15 | Novo Nordisk As | STABILIZED PHARMACEUTICAL GLP-1 PEPTIDE COMPOSITIONS |
US8491571B2 (en) * | 2003-06-12 | 2013-07-23 | Cordis Corporation | Orifice device having multiple channels with varying flow rates for drug delivery |
US7205409B2 (en) | 2003-09-04 | 2007-04-17 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
AU2004277980A1 (en) | 2003-09-30 | 2005-04-14 | Alza Corporation | Osmotically driven active agent delivery device providing an ascending release profile |
US7407499B2 (en) | 2003-10-31 | 2008-08-05 | Intarcia Therapeutics, Inc. | Osmotic pump with self-retaining, fast-start membrane plug |
WO2005046639A2 (en) | 2003-11-06 | 2005-05-26 | Alza Corporation | Modular imbibition rate reducer for use with implantable osmotic pump |
US20050118206A1 (en) | 2003-11-14 | 2005-06-02 | Luk Andrew S. | Surfactant-based gel as an injectable, sustained drug delivery vehicle |
US20050106214A1 (en) | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
US20050281879A1 (en) | 2003-11-14 | 2005-12-22 | Guohua Chen | Excipients in drug delivery vehicles |
US7780973B2 (en) | 2003-12-15 | 2010-08-24 | Ethicon Endo-Surgery, Inc. | Method and device for minimally invasive implantation of biomaterial |
US20050175701A1 (en) | 2004-02-10 | 2005-08-11 | Alza Corporation | Capillary moderator for osmotic delivery system |
US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
AU2005211755B2 (en) | 2004-02-11 | 2012-03-15 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
MXPA06011924A (en) | 2004-04-15 | 2007-06-11 | Alkermes Inc | Polymer-based sustained release device. |
US7456254B2 (en) | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
US20050266087A1 (en) | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
US20090042781A1 (en) | 2004-06-28 | 2009-02-12 | Novo Nordisk A/S | Methods for Treating Diabetes |
US7772182B2 (en) | 2004-08-05 | 2010-08-10 | Alza Corporation | Stable suspension formulations of erythropoietin receptor agonists |
GB2434189B (en) | 2004-08-18 | 2009-04-01 | Waters Investments Ltd | Defined leak path for high pressure seal |
US8268791B2 (en) | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
US7442682B2 (en) | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
WO2006052608A2 (en) | 2004-11-01 | 2006-05-18 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
US20060141040A1 (en) | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
US20060142234A1 (en) | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
EP1841448A2 (en) | 2004-12-30 | 2007-10-10 | Diakine Therapeutics, Inc. | Pharmaceutical compositions and methods for restoring beta-cell mass and function |
AU2006208131A1 (en) | 2005-01-25 | 2006-08-03 | Microchips, Inc. | Control of drug release by transient modification of local microenvironments |
US20060216242A1 (en) | 2005-02-03 | 2006-09-28 | Rohloff Catherine M | Suspending vehicles and pharmaceutical suspensions for drug dosage forms |
EP1877077A2 (en) | 2005-02-03 | 2008-01-16 | Intarcia Therapeutics, Inc. | An implantable interferon-containing device |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
US7959938B2 (en) | 2005-03-15 | 2011-06-14 | Intarcia Therapeutics, Inc. | Polyoxaester suspending vehicles for use with implantable delivery systems |
EA013121B1 (en) | 2005-03-31 | 2010-02-26 | Амилин Фармасьютикалз, Инк. | Amylin and amylin agonists for treating psychiatric diseases and disorders |
ATE509634T1 (en) | 2005-04-08 | 2011-06-15 | Amylin Pharmaceuticals Inc | PHARMACEUTICAL FORMULATIONS CONTAINING INCRETIN PEPTIDE AND APROTIC-POLAR SOLVENT |
JP2008536881A (en) | 2005-04-21 | 2008-09-11 | ガストロテック・ファルマ・アクティーゼルスカブ | Pharmaceutical formulation of GLP-1 molecule and antiemetic |
US7699833B2 (en) | 2005-05-06 | 2010-04-20 | Moberg Sheldon B | Pump assembly and method for infusion device |
US20060280795A1 (en) | 2005-06-08 | 2006-12-14 | Dexcel Pharma Technologies, Ltd. | Specific time-delayed burst profile delivery system |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
AU2006279680B2 (en) | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
US8389472B2 (en) | 2005-08-19 | 2013-03-05 | Amylin Pharmaceuticals, Llc | Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
HUE064811T2 (en) | 2005-08-19 | 2024-04-28 | Amylin Pharmaceuticals Llc | Exendin for use in treating diabetes and reducing body weight |
JP2009514900A (en) | 2005-11-04 | 2009-04-09 | スミスクライン・ビーチャム・コーポレイション | Administration method of hypoglycemic agent |
US8293869B2 (en) | 2005-12-16 | 2012-10-23 | Nektar Therapeutics | Polymer conjugates of GLP-1 |
CA2634016A1 (en) | 2005-12-16 | 2007-07-05 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating obesity and related metabolic disorders |
WO2007084460A2 (en) | 2006-01-18 | 2007-07-26 | Qps, Llc | Pharmaceutical compositions with enhanced stability |
CN101432025B (en) | 2006-03-21 | 2012-04-04 | 安米林药品公司 | Peptide-peptidase inhibitor conjugates and methods of using same |
AU2007247137A1 (en) | 2006-05-02 | 2007-11-15 | Actogenix N.V. | Microbial intestinal delivery of obesity related peptides |
WO2007133778A2 (en) | 2006-05-12 | 2007-11-22 | Amylin Pharmaceuticals, Inc. | Methods to restore glycemic control |
JP5143131B2 (en) * | 2006-05-30 | 2013-02-13 | インターシア セラピューティクス,インコーポレイティド | Two-piece internal channel flow modulator for osmotic delivery system |
GB0613196D0 (en) | 2006-07-03 | 2006-08-09 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
US8501693B2 (en) | 2006-08-04 | 2013-08-06 | Amylin Pharmaceuticals, Llc | Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen |
PL2359808T3 (en) | 2006-08-09 | 2013-10-31 | Intarcia Therapeutics Inc | Osmotic delivery systems and piston assemblies |
WO2008061355A1 (en) | 2006-11-24 | 2008-05-29 | Matregen Corp. | Glp-1 depot systems, and methods of manufacture and uses thereof |
TWI428346B (en) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
WO2008092084A2 (en) | 2007-01-26 | 2008-07-31 | Centocor, Inc. | Injectable non-aqueous suspension with high concentration of therapeutic agent |
CA2683610C (en) | 2007-04-23 | 2013-01-08 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
US8236760B2 (en) | 2007-04-27 | 2012-08-07 | Cedars-Sinsai Medical Center | Use of GLP-1 receptor agonists for the treatment of short bowel syndrome |
US20090202481A1 (en) | 2008-02-08 | 2009-08-13 | Qps Llc | Composition for Sustained Release Delivery of Proteins or Peptides |
DK2240155T3 (en) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Devices, formulations and methods for the delivery of several beneficial agents |
AU2009214632B2 (en) | 2008-02-14 | 2015-02-19 | Reshape Lifesciences, Inc. | Treatment of excess weight by neural downregulation in combination with compositions |
US20110046071A1 (en) | 2008-03-05 | 2011-02-24 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer |
EP2343982B1 (en) | 2008-09-17 | 2017-03-22 | Chiasma Inc. | Pharmaceutical compositions and related methods of delivery |
CN102281865B (en) | 2008-10-15 | 2017-04-05 | 精达制药公司 | Highly enriched drug particles, preparation, suspensoid and its application |
KR101823699B1 (en) | 2009-09-28 | 2018-01-30 | 인타르시아 세라퓨틱스 인코포레이티드 | Rapid establishment and/or termination of substantial steady-state drug delivery |
AR079345A1 (en) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | OXINTOMODULINE PEPTIDAL ANALOG |
WO2011156407A2 (en) | 2010-06-09 | 2011-12-15 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonists to treat pancre-atitis |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
-
2007
- 2007-05-30 JP JP2009513435A patent/JP5143131B2/en active Active
- 2007-05-30 EP EP07797884A patent/EP2020990B1/en active Active
- 2007-05-30 ES ES07797884T patent/ES2351527T3/en active Active
- 2007-05-30 NZ NZ572003A patent/NZ572003A/en unknown
- 2007-05-30 CN CN2007800187567A patent/CN101453982B/en active Active
- 2007-05-30 CA CA2651855A patent/CA2651855C/en active Active
- 2007-05-30 AT AT07797884T patent/ATE481963T1/en not_active IP Right Cessation
- 2007-05-30 AU AU2007266475A patent/AU2007266475B2/en active Active
- 2007-05-30 DK DK07797884.9T patent/DK2020990T3/en active
- 2007-05-30 DE DE602007009377T patent/DE602007009377D1/en active Active
- 2007-05-30 KR KR1020087028256A patent/KR101106510B1/en active IP Right Grant
- 2007-05-30 US US11/755,494 patent/US8052996B2/en active Active
- 2007-05-30 MX MX2008014870A patent/MX2008014870A/en active IP Right Grant
- 2007-05-30 WO PCT/US2007/069990 patent/WO2007140416A2/en active Application Filing
-
2008
- 2008-10-22 IL IL194746A patent/IL194746A/en active IP Right Grant
-
2009
- 2009-08-10 HK HK09107318.1A patent/HK1129203A1/en unknown
-
2011
- 2011-08-12 US US13/209,328 patent/US8158150B2/en active Active
-
2012
- 2012-03-29 US US13/433,287 patent/US8273365B2/en active Active
- 2012-08-31 US US13/601,939 patent/US8367095B2/en active Active
-
2013
- 2013-01-12 US US13/740,187 patent/US8470353B2/en active Active
- 2013-05-20 US US13/898,358 patent/US8992962B2/en active Active
-
2015
- 2015-02-26 US US14/632,700 patent/US9539200B2/en active Active
-
2016
- 2016-11-09 US US15/347,261 patent/US20170181964A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6524305B1 (en) * | 1997-07-25 | 2003-02-25 | Alza Corporation | Osmotic delivery system flow modulator apparatus and method |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101453982B (en) | Two-piece, internal-channel osmotic delivery system flow modulator | |
AU2002315374B2 (en) | Osmotic implant with membrane and membrane retention means | |
US20080269726A1 (en) | Osmotic pump with self-retaining, fast-start membrane plug | |
NO314223B1 (en) | Osmotic system for delivering fluid-sensitive somatotropin to bovine animals | |
AU2012330960B2 (en) | Osmotically active vaginal delivery system | |
KR20050120767A (en) | Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1129203 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1129203 Country of ref document: HK |